10:39 AM EST - Neovasc Inc. : Announced the publication of a case series in the journal Cardiovascular Revascularization Medicine describing successful uses of the Neovasc Reducer under a compassionate use protocol in the United States. Following the commencement of the COSIRA-II Trial in the United States, qualifying patients are now eligible to be treated in a clinical trial for the device. Neovasc Inc.
shares T.NVCN are trading up $0.02 at $0.60.
